TGTX FY 2022 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-58.4% YoY

Gross Profit

$3M90.5% margin

Operating Income

-$218M-7839.0% margin

Net Income

-$224M-8036.3% margin

EPS (Diluted)

$-1.46

Cash Flow

Operating Cash Flow

-$176M

Free Cash Flow

-$176M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$194M

Total Liabilities

$135M

Stockholders' Equity

$59M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$7M	-58.4%
Gross Profit	$3M	$6M	-57.3%
Operating Income	-$218M	-$345M	+36.7%
Net Income	-$224M	-$348M	+35.7%